TScan Therapeutics: CFO and CMO to Depart Under Separation Agreements

What Happened

• TScan Therapeutics filed an 8-K (Sept. 30, 2026) disclosing that, as part of a strategic reorganization, CFO Jason A. Amello and CMO Chrystal Louis, M.D., MPH, will cease serving in their roles. The company entered into Confidential Separation and General Release Agreements with Dr. Louis (Sept. 24, 2026) and Mr. Amello (Sept. 25, 2026). Each executive’s employment will terminate on the earlier of November 1, 2026 or the date they begin other paid work; base salary and employee benefits will continue through that date.

Key Details

• Agreements signed: Dr. Louis on Sept. 24, 2026; Mr. Amello on Sept. 25, 2026.
• Separation date: earlier of Nov. 1, 2026 or the executive’s start of other employment/consulting/paid board service.
• Compensation continuity: base salary and benefits continue until Separation Date.
• Additional payments: Amello retains previously disclosed termination benefits and may receive a $85,000 lump-sum under the company’s Nov. 2025 retention program if a specified milestone is achieved before his Separation Date; Dr. Louis retains previously disclosed termination benefits and may receive $125,000 under the same milestone condition.
• Full Separation Agreement texts will be filed as exhibits to TScan’s Form 10-Q for the quarter ended Sept. 30, 2026.

Why It Matters

• Executive departures: Losing the CFO and CMO are material leadership changes that investors should note as part of the company’s strategic reorganization.
• Financial impact: The disclosed potential cash obligations are limited and milestone-contingent ($85k and $125k) in addition to previously disclosed termination amounts; whether those payments occur depends on the timing of the milestone and each executive’s Separation Date.
• What to watch next: Review the upcoming Form 10-Q (quarter ended Sept. 30, 2026) for the full separation agreements and any additional disclosure about management changes or cash impacts.